Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa infection in a murine burn wound model

被引:29
作者
Felts, AG
Giridhar, G
Grainger, DW
Slunt, JB
机构
[1] GAMMA-A Technologies, Inc., 520 Huntmar Park Drive, Herndon
关键词
burns; wound infection; antibodies;
D O I
10.1016/S0305-4179(99)00017-0
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The leading cause of morbidity and mortality in severe burn wound patients is infection. Treatment of burn wound infection is complicated by the emergence of antibiotic resistant organisms. A potential therapeutic alternative to antibiotic drugs is the local administration of polyclonal antibodies, termed passive local immunotherapy (PLI), directly to the burned tissue. A mouse burn wound infection model to simulate full thickness burn wound infection was used to evaluate the efficacy of passive local immunotherapy as a viable prophylactic or therapeutic agent. Pooled human immunoglobulins (IgG), delivered locally to the site of infection, are shown to be mon effective at preventing fatal burn wound sepsis than treatment by intravenous infusion of IgG. A single 10 mg dose of human IgG administered locally to the burned, infected tissue site, either 24 hours prior to bacterial challenge, or within 3 hours after bacterial challenge, enhanced animal survival significantly (P < 0.001 and P < 0.05 respectively) compared to control animals. In addition, reduced levels of bacteria were found in local and systemic tissues of IgG-treated mice compared to control mice (P < 0.05). These data support the local use of polyclonal immunoglobulin preparations as an efficacious and cost effective means to prevent and treat burn wound infections. (C) 1999 Elsevier Science Ltd and ISBI. All rights reserved.
引用
收藏
页码:415 / 423
页数:9
相关论文
共 46 条
[1]  
BAREKZI NA, 1998, IN PRESS ANTIMICROB
[2]  
BAUMGARTNER JD, 1987, REV INFECT DIS, V9, P194
[3]  
BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207
[4]   Crisis in infectious diseases: Time for a new paradigm? [J].
Casadevall, A .
CLINICAL INFECTIOUS DISEASES, 1996, 23 (04) :790-794
[5]   RETURN TO THE PAST - THE CASE FOR ANTIBODY-BASED THERAPIES IN INFECTIOUS-DISEASES [J].
CASADEVALL, A ;
SCHARFF, MD .
CLINICAL INFECTIOUS DISEASES, 1995, 21 (01) :150-161
[6]   PATTERNS OF STAPHYLOCOCCUS-AUREUS COLONIZATION, TOXIN PRODUCTION, IMMUNITY AND ILLNESS IN BURNED CHILDREN [J].
CHILDS, C ;
EDWARDSJONES, V ;
HEATHCOTE, DM ;
DAWSON, M ;
DAVENPORT, PJ .
BURNS, 1994, 20 (06) :514-521
[7]  
COMETTA A, 1994, CLIN EXP IMMUNOL, V97, P69
[8]  
CROSS AS, 1995, IMMUNOBIOLOGY PROTEI, V8, P123
[9]   EFFECTS OF PROPHYLACTIC INTRAVENOUS IMMUNOGLOBULIN-G THERAPY ON HUMORAL AND CELLULAR IMMUNE COMPONENTS AND THEIR FUNCTIONS IN BURNED PATIENTS [J].
DIBIRDIK, I ;
DURAK, N ;
KISLAOGLU, E ;
KUTLUAY, T ;
AYTEMIZ, C .
BURNS, 1995, 21 (02) :130-135
[10]  
DUHEM C, 1994, CLIN EXP IMMUNOL, V97, P79